2.93

1.74% 0.05

After Hours: 2.85 -0.08 -2.73%

Anixa Biosciences Inc (ANIX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Anixa Biosciences Inc stock is traded at $2.93, with a volume of 90,593. It is up +1.74% in the last 24 hours and up +3.53% over the past month. Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Previous Close:

$2.88

Open:

$2.86

24h Volume:

90,593

Relative Volume:

0.60

Market Cap:

$98.24M

Revenue:

$210.00K

Net Income/Loss:

$-10.40M

P/E Ratio:

-9.3045

EPS:

-0.3149

Net Cash Flow:

$-6.88M

1W Performance:

+7.33%

1M Performance:

+3.53%

6M Performance:

-34.45%

1Y Performance:

+2.81%

1-Day Range:

$2.785

$2.93

1-Week Range:

$2.6197

$2.93

52-Week Range:

$2.44

$5.4566

Anixa Biosciences Inc Stock (ANIX) Company Profile

Name

Anixa Biosciences Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

408-708-9808

Address

3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE

Employee

Twitter

@anixabio

Next Earnings Date

2026-03-10

Latest SEC Filings

ANIX's Discussions on Twitter

Compare ANIX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANIX Anixa Biosciences Inc	2.93	96.56M	210.00K	-10.40M	-6.88M	-0.3149
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-21-25	Initiated	Maxim Group	Buy
Dec-23-22	Initiated	Chardan Capital Markets	Buy
Apr-12-21	Initiated	H.C. Wainwright	Buy

Anixa Biosciences Inc Stock (ANIX) Latest News

Apr 14, 2026

Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan at Conference - Yahoo Finance

Apr 14, 2026

Apr 13, 2026

Weekly Trades: Does Anixa Biosciences Inc have declining or rising EPS2026 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn

Apr 13, 2026

Aug Macro: Can Anixa Biosciences Inc maintain its current growth rate2026 Analyst Calls & Consistent Profit Trade Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 10, 2026

AVAX Technologies and Anixa Biosciences Compared in Critical Analysis - National Today

Apr 10, 2026

Apr 09, 2026

Earnings Risk: Does Anixa Biosciences Inc have declining or rising EPSWeekly Trend Recap & Daily Growth Stock Investment Tips - baoquankhu1.vn

Apr 09, 2026

Anixa Biosciences Reports Positive Clinical Trial Results for Cancer Vaccines - Intellectia AI

Apr 09, 2026

Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026 - Finviz

Apr 09, 2026

At April 16 event, Anixa will spotlight 74% immune response data - Stock Titan

Apr 09, 2026

Apr 08, 2026

Anixa Biosciences Price Target Maintained With a $10.00/Share by D. Boral Capital - Moomoo

Apr 08, 2026

ANIX Stock: Consistent 'Buy' Rating and Price Target Maintained - GuruFocus

Apr 08, 2026

Anixa Biosciences' (ANIX) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat

Apr 08, 2026

Apr 07, 2026

Anixa Biosciences to Present at Water Tower Research Insights Conference - National Today

Apr 07, 2026

74% vaccine response, CAR-T survival data on Anixa's April 14 agenda - Stock Titan

Apr 07, 2026

Apr 06, 2026

Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs - Barchart

Apr 06, 2026

Apr 04, 2026

Anixa Biosciences (NASDAQ:ANIX) Stock Rating Lowered by Wall Street Zen - MarketBeat

Apr 04, 2026

Apr 02, 2026

Anixa partners with Cytovance for breast cancer vaccine trial By Investing.com - Investing.com South Africa

Apr 02, 2026

ANIX Stock Price, Quote & Chart | ANIXA BIOSCIENCES INC (NASDAQ:ANIX) - ChartMill

Apr 02, 2026

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - Sahm

Apr 02, 2026

Apr 01, 2026

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 - GuruFocus

Apr 01, 2026

Anixa Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results - Oncodaily

Apr 01, 2026

Eli Lilly, Space stocks, Anixa Biosciences - TradingView — Track All Markets

Apr 01, 2026

Anixa Biosciences (ANIX) Advances Breast Cancer Vaccine with New Manufacturing Agreement - GuruFocus

Apr 01, 2026

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 with Selection of Cytovance Biologics for cGMP Manufacturing - irw-press.com

Apr 01, 2026

Anixa partners with Cytovance for breast cancer vaccine trial - Investing.com

Apr 01, 2026

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results Cytovance Selected For Cgmp Manufacturing - TradingView

Apr 01, 2026